Autologous Tumor Lysate–Loaded Dendritic Cell Vaccination Extends Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
JAMA Oncol 2022 Nov 17;[EPub Ahead of Print], LM Liau, K Ashkan, S Brem, JL Campian, JE Trusheim, FM Iwamoto, DD Tran, G Ansstas, CS Cobbs, JA Heth, ME Salacz, S D'Andre, RD Aiken, YA Moshel, JY Nam, CP Pillainayagam, SA Wagner, KA Walter, R Chaudary, SA Goldlust, IY Lee, DA Bota, H Elinzano, J Grewal, K Lillehei, T Mikkelsen, T Walbert, S Abram, AJ Brenner, MG Ewend, S Khagi, DS Lovick, J Portnow, L Kim, WG Loudon, NL Martinez, RC Thompson, DE Avigan, KL Fink, FJ Geoffroy, P Giglio, O Gligich, D Krex, SM Lindhorst, J Lutzky, HJ Meisel, M Nadji-Ohl, L Sanchin, A Sloan, LP Taylor, JK Wu, EM Dunbar, AB Etame, S Kesari, D Mathieu, DE Piccioni, DS Baskin, M Lacroix, SA May, PZ New, TJ Pluard, SA Toms, V Tse, S Peak, JL Villano, JD Battiste, PJ Mulholland, ML Pearlman, K Petrecca, M Schulder, RM Prins, AL Boynton, ML BoschFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.